Matinas BioPharma's Oral MAT2203 to Be Discussed in A.G.P. Chat with Antifungal Expert Dr. David S. Perlin

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical firm specializing in innovative treatments through its lipid nanocrystal (LNC) platform, announced a notable upcoming event featuring MAT2203, its oral formulation of the potent antifungal amphotericin B. This discussion will take place on June 18, 2024, and will be led by Dr. David S. Perlin, a prominent authority in antifungal therapies, hosted by Scott Henry from Alliance Global Partners.

The discussion will cover various key points, including a detailed analysis of the antifungal treatment market and current therapeutic options, the clinical prospects of MAT2203 as an oral formulation of amphotericin B, and the potential market opportunities for MAT2203. Additionally, the talk will delve into the design and critical aspects of the MAT2203 ORALTO pivotal trial, particularly focusing on patients with invasive aspergillosis who have limited treatment alternatives.

The event will also feature a Q&A session where participants can pose questions to the experts through the event platform. Those interested in attending can register online, and an archived webcast of the discussion will be available for 60 days post-event.

Dr. David Perlin, currently the Chief Scientific Officer and Executive Vice President at the Hackensack Meridian Center for Discovery and Innovation, will be the key speaker. Dr. Perlin's work aims to swiftly translate scientific innovations into tangible patient benefits, particularly for those suffering from cancer, infectious diseases, and other severe health conditions. With over 30 years of continuous research funding from the National Institutes of Health (NIH), Dr. Perlin has been instrumental in developing new therapeutics and diagnostics against high-risk pathogens. He has published more than 320 papers and book chapters and has co-authored two books. His career also includes advisory roles for the NIH, Bill & Melinda Gates Foundation, and several other prominent organizations and companies.

MAT2203 represents a significant advancement in the treatment of invasive fungal infections. Amphotericin B, while effective, currently requires intravenous administration, which can lead to severe side effects like renal toxicity and anemia due to high circulating levels. MAT2203, by contrast, offers targeted oral delivery, matching the fungicidal activity of amphotericin B while reducing the associated risks, potentially making it an ideal treatment for such infections.

MAT2203 has demonstrated success in clinical trials, including the Phase 2 EnACT study in HIV patients with cryptococcal meningitis, achieving its primary endpoint and showing strong survival rates. The upcoming Phase 3 ORALTO trial will further evaluate MAT2203 as an oral step-down monotherapy following initial treatment with AmBisome in patients with invasive aspergillosis, comparing it to the standard of care for these patients.

Matinas BioPharma is dedicated to revolutionizing treatment options through its LNC platform, which has shown promise in both preclinical and clinical settings. This technology offers a solution to the challenges of safe and effective intracellular delivery of various molecular cargos, including small molecules and larger, complex molecules like ASOs and siRNA. The versatility and unique mechanism of action of the LNC platform position it as a potentially preferred method for next-generation orally available intracellular drug delivery.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!